Oramed Pharmaceuticals (FRA:OJU1) ROCE % : 5.05% (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Oramed Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Oramed Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was 5.05%.

Oramed Pharmaceuticals ROCE % Historical Data

The historical data trend for Oramed Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals ROCE % Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-41.43

-32.97

-30.06

-28.41

4.35

Oramed Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-9.25	-9.72	-6.43	35.89	5.05

Oramed Pharmaceuticals ROCE % Calculation

Oramed Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	6.534	/	( ( (152.59 - 5.424)	+	(202.245 - 48.797) )	/ 2 )
	=	6.534	/	( (147.166	+	153.448)	/ 2 )
	=	6.534	/	150.307
	=	4.35 %

Oramed Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	7.824	/	( ( (202.245 - 48.797)	+	(187.36 - 30.872) )	/ 2 )
	=	7.824	/	( ( 153.448	+	156.488 )	/ 2 )
	=	7.824	/	154.968
	=	5.05 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Oramed Pharmaceuticals (FRA:OJU1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Oramed Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (FRA:OJU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (FRA:OJU1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ORMP:USA

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.

Oramed Pharmaceuticals (FRA:OJU1) Headlines

No Headlines